Comparative Effects of a2 Platinum Stage 1 Infant Formula on Infant Digestion and Comfort

Healthy Infants Clinical Trial

Official title:

Protocol Title: Comparative Effects of a2 Platinum® Stage 1 Infant Formula Versus Conventional Stage 1 Infant Formula Containing A1 and A2 β-casein Versus Breast Feeding on Infant Digestion and Comfort: A Single-blind Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04733937
• Other study ID #: A2MC-G190549140
• Status: Completed
• Phase: N/A
• Start date: December 4, 2020
• Est. completion date: April 16, 2022

Study information

• Verified date: November 2022
• Source: a2 Milk Company Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is a single-blind, randomized, controlled, parallel-designed trial to compare the effects of a2 Platinum® stage 1 infant formula versus conventional, A1 and A2 β-casein-containing stage 1 infant formula versus breastfeeding on crying, tolerance, gut health, and immune function.

Description:

The protocol was updated from V8.2 to V9.1 and was approved by the Ethical Committee of Shanghai First Maternity and Infant Hospital, the main site. The major changes are: from "blind to participants" to "non-blind to participants"; from "Single-Centre" to "Multi-Centre"; number of subjects from "270" to "180"; trial period from "3 weeks" to "4 weeks"; and number of visits from "6" to "4".

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: April 16, 2022
• Est. primary completion date: April 16, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 0 Days to 76 Days

Eligibility

Inclusion Criteria:

1. 0-76 days of age after birth, inclusive (day of birth is considered day 0)

2. Singleton birth

3. Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks gestational age)

4. Birth weight of 2,500 g to 4,500 g

5. Signed informed consent obtained for infant's participation in the survey

6. Parent or guardian of infant agrees not to enrol infant in another interventional clinical survey while participating in this survey

7. Parent or guardian agrees to formula-feed the baby as per the randomization schedule For the formula-fed groups, participants in addition to the above-listed criteria, must

also meet the following criterion:

• Parent or guardian agrees that the baby will be fed with standardized formula upon enrolment and switched to randomized formula at baseline (90-105 days of age) For the breastfed group, participants in addition to the above-listed criteria, must also

meet the following criterion:

• Parent or guardian agrees that the baby will be breast-fed

Exclusion Criteria:

1. Infant with inborn malformation and with hereditary and/or chronic and/or inborn diseases that could interfere with the survey (e.g. being unable to breast-feed or formula-fed)

2. Diseases jeopardizing intrauterine growth

3. Known or increased risk of IgE-mediated cow's milk protein allergy

1. (i.e. one of the biological parents and/or siblings diagnosed with similar allergy,

2. asthma, hay fever, etc.)

4. Infant with an acute infection or gastroenteritis at time of randomization

5. Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake at time of randomization

6. Participation in another clinical trial

7. Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements (including to fill in the diaries and to wait with introducing weaning foods until 4 months of age, and capability and willingness to do stool sample collection, handling, processing, and storage as instructed)

8. Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiencies such as combined immunodeficiencies, DiGeorge Syndrome, Wiskott-Aldrich syndrome, severe congenital neutropenia and secondary immunodeficiencies linked to HIV infection, Down Syndrome or others) and children with known head/brain disease/injury such as microcephaly, macrocephaly or others

Exit Criteria:

1. Ineligibility (either arising during the trial or retrospectively having been overlooked at screening)

2. Significant protocol deviation

3. Significant non-compliance with product regimen or trial requirements

4. An adverse event (including one occurring before the start of the trial period) which requires discontinuation of the trial product or results in inability to continue to comply with trial procedures

5. Disease progression which requires discontinuation of the trial product or results in inability to continue to comply with trial procedures

6. Withdrawal of Consent

7. Lost to follow up

8. Weight at Visit 2 is <95% of birth weight [(weight at Visit 2÷birth weight) x 100 <95%]

9. Use of antibiotics, steroids or prebiotics/probiotics anytime between 14 days before baseline and trial completion

10. Participant whose mother has used any form of antibiotics or steroids while breastfeeding

11. More than 1 feed of formula milk per day for the breastfed group

12. More than 2 feeds of breast milk per day for the formula groups

Related Conditions & MeSH terms

• Healthy Infants

Intervention

Other:
• a2 Platinum® stage 1 infant formula
Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
• Conventional, A1 and A2 ß-casein containing stage 1 infant formula
Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.

Locations

Country	Name	City	State
China	Second Hospital of Jilin University	Changchun	Jilin
China	Women & Children's Health Care Hospital of Linyi, China	Linyi	Shandong
China	Nanjing Maternity and Child Health Care Hospital	Nanjing	Jiangsu
China	Shanghai First Maternity and Infant Hospital	Shanghai	Shanghai
China	First Teaching Hospital of Tianjin University of Traditional Chinese Medicine	Tianjin	Tianjin

Sponsors (9)

Lead Sponsor	Collaborator
a2 Milk Company Ltd.	Beijing Esmile Technology Co. Ltd., Edanz Group Japan Ltd, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nanjing Maternity and Child Health Care Hospital, Second Hospital of Jilin University, Shanghai First Maternity and Infant Hospital, Women & Children's Health Care Hospital of Linyi, China, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes of crying frequency at each follow up visit compared to baseline	Record frequency of crying (times/d)	Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 days after baseline); Visit 4 (28 days after baseline)
Primary	Changes of crying duration at each follow up visit compared to baseline	Record duration of crying (min)	Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 day after baseline); Visit 4 (28 days after baseline)
Primary	Changes in fecal MPO levels at each follow up visit compared to baseline	Record fecal MPO (in Unit) as markers of inflammation	Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 day after baseline); Visit 4 (28 days after baseline)
Secondary	Changes in salivary cortisol levels at each follow up visit compared to baseline	Record salivary cortisol (nmol/L) as markers of immune function	Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 day after baseline); Visit 4 (28 days after baseline)
Secondary	Changes in body length	Differences in length gain (cm/d)	Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 days after baseline); Visit 4 (28 days after baseline)
Secondary	Changes in body weight	Differences in weight gain (kg/d)	Visit 1 (screening/randomization); Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 day after baseline); Visit 4 (28 days after baseline)
Secondary	Changes in head circumference	Differences in head circumference (cm/d)	Visit 1 (screening/randomization); Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 day after baseline); Visit 4 (28 days after baseline)
Secondary	Number of adverse events at each follow up visit compared to baseline	Record number of adverse events as a measure of safety and tolerability	Visit 1 (screening/randomization); Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 day after baseline); Visit 4 (28 days after baseline)
Secondary	Abundance analysis of gut microflora species	Differences in abundance of gut microflora species	Visit 2 (baseline [90-105 days since birth]); Visit 3 (14 days after baseline); Visit 4 (28 days after baseline)